$1.90
5.00% yesterday
Nasdaq, Aug 11, 10:00 pm CET

ImmunoPrecise Antibodies Ltd Target price 2025 - Analyst rating & recommendation

ImmunoPrecise Antibodies Ltd Classifications & Recommendation:

Buy
83%
Hold
17%

ImmunoPrecise Antibodies Ltd Price Target

Target Price $4.08
Price $1.90
Potential
Number of Estimates 3
3 Analysts have issued a price target ImmunoPrecise Antibodies Ltd 2026 . The average ImmunoPrecise Antibodies Ltd target price is $4.08. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 5 Analysts recommend ImmunoPrecise Antibodies Ltd to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the ImmunoPrecise Antibodies Ltd stock has an average upside potential 2026 of . Most analysts recommend the ImmunoPrecise Antibodies Ltd stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Apr '24 2025
Estimates
Revenue Million $ 17.79 18.62
18.68% 4.68%
Net Margin -110.85% -113.48%
13.77% 2.37%

3 Analysts have issued a sales forecast ImmunoPrecise Antibodies Ltd 2025 . The average ImmunoPrecise Antibodies Ltd sales estimate is

$18.6m
Unlock
. This is
6.96% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$19.9m 14.31%
Unlock
, the lowest is
$17.6m 0.89%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $17.8m 18.68%
2025
$18.6m 4.68%
Unlock
2026
$21.3m 14.15%
Unlock
2027
$28.1m 32.09%
Unlock
2028
$30.9m 10.11%
Unlock
2029
$35.7m 15.58%
Unlock
2030
$42.0m 17.45%
Unlock
2031
$49.9m 18.90%
Unlock
2032
$59.7m 19.54%
Unlock

3 ImmunoPrecise Antibodies Ltd Analysts have issued a net profit forecast 2025. The average ImmunoPrecise Antibodies Ltd net profit estimate is

$-21.1m
Unlock
. This is
36.85% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-8.7m 73.94%
Unlock
, the lowest is
$-32.9m 1.76%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-19.7m 2.34%
2025
$-21.1m 7.15%
Unlock
2026
$-3.7m 82.54%
Unlock
2027
$670k 118.16%
Unlock

Net Margin

2024 -110.85% 13.77%
2025
-113.48% 2.37%
Unlock
2026
-17.36% 84.70%
Unlock
2027
2.39% 113.77%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Apr '24 2025
Estimates
Earnings Per Share $ -0.77 -0.46
1.28% 40.26%
P/E negative
EV/Sales 4.71

3 Analysts have issued a ImmunoPrecise Antibodies Ltd forecast for earnings per share. The average ImmunoPrecise Antibodies Ltd EPS is

$-0.46
Unlock
. This is
54.90% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.19 81.37%
Unlock
, the lowest is
$-0.72 29.41%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.77 1.28%
2025
$-0.46 40.26%
Unlock
2026
$-0.08 82.61%
Unlock
2027
$0.01 112.50%
Unlock

P/E ratio

Current -1.86 88.84%
2025
-4.12 121.18%
Unlock
2026
-23.57 472.09%
Unlock
2027
129.63 649.98%
Unlock

Based on analysts' sales estimates for 2025, the ImmunoPrecise Antibodies Ltd stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.04 207.32%
2025
4.71 6.56%
Unlock
2026
4.13 12.39%
Unlock
2027
3.12 24.30%
Unlock
2028
2.84 9.18%
Unlock
2029
2.45 13.48%
Unlock
2030
2.09 14.86%
Unlock
2031
1.76 15.90%
Unlock
2032
1.47 16.34%
Unlock

P/S ratio

Current 5.04 343.35%
2025
4.71 6.51%
Unlock
2026
4.13 12.39%
Unlock
2027
3.12 24.30%
Unlock
2028
2.84 9.18%
Unlock
2029
2.45 13.48%
Unlock
2030
2.09 14.86%
Unlock
2031
1.76 15.90%
Unlock
2032
1.47 16.34%
Unlock

Current ImmunoPrecise Antibodies Ltd Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Apr 11 2025
Benchmark
Locked
Locked
Locked Apr 01 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 31 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 14 2025
HC Wainwright & Co.
Locked
Locked
Locked Dec 11 2024
HC Wainwright & Co.
Locked
Locked
Locked Sep 17 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 11 2025
Locked
Benchmark:
Locked
Locked
Apr 01 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 31 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 14 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Dec 11 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 17 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today